SWM
TARS icon

Spire Wealth Management’s Tarsus Pharmaceuticals TARS Stock Holding History

Spire Wealth Management’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-143
Closed -$11.7K – 2398
2025
Q4 		$11.7K Sell
143
-84
-37% -$6.27K ﹤0.01% 1659
2025
Q3 		$13.5K Hold
227
– – ﹤0.01% 1646
2025
Q2 		$9.2K Sell
227
-146
-39% -$6.57K ﹤0.01% 1747
2025
Q1 		$19.2K Buy
373
+230
+161% +$11.4K ﹤0.01% 1625
2024
Q4 		$7.92K Sell
143
-84
-37% -$3.81K ﹤0.01% 1906
2024
Q3 		$7.47K Sell
227
-33
-13% -$928 ﹤0.01% 1722
2024
Q2 		$7.07K Buy
260
+127
+95% +$4.27K ﹤0.01% 1742
2024
Q1 		$4.83K Buy
133
+67
+102% +$1.97K ﹤0.01% 1936
2023
Q4 		$1.55K Sell
66
-80
-55% -$1.34K ﹤0.01% 2193
2023
Q3 		$2.59K Hold
146
– – ﹤0.01% 2076
2023
Q2 		$2.64K Buy
146
+43
+42% +$684 ﹤0.01% 2146
2023
Q1 		$1.29K Buy
+103
New +$1.51K ﹤0.01% 2356
2022
Q3 		– Sell
-50
Closed -$1K – 2570
2022
Q2 		$1K Sell
50
-50
-50% -$751 ﹤0.01% 2579
2022
Q1 		$2K Hold
100
– – ﹤0.01% 2420
2021
Q4 		$2K Hold
100
– – ﹤0.01% 2802
2021
Q3 		$2K Hold
100
– – ﹤0.01% 2486
2021
Q2 		$3K Hold
100
– – ﹤0.01% 2436
2021
Q1 		$3K Buy
+100
New +$3.7K ﹤0.01% 2777

Other funds holding TARS

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Spire Wealth Management's TARS Position: Q1 2026 in Review

Spire Wealth Management sold out of Tarsus Pharmaceuticals (TARS) in Q1 2026, closing a stake of 143 shares — an estimated $11.7K sold.

Spire Wealth Management first reported a position in TARS in Q1 2021 and held it in 18 quarters. The position peaked at $19.2K in Q1 2025. 253 funds tracked by Wall St. Rank hold TARS as of Q1 2026.

  • Spire Wealth Management reported no remaining Tarsus Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Spire Wealth Management sold 143 Tarsus Pharmaceuticals shares in Q1 2026, an estimated $11.7K.
  • Spire Wealth Management first reported a position in Tarsus Pharmaceuticals in Q1 2021 and held it in 18 quarters.
  • Spire Wealth Management's Tarsus Pharmaceuticals position peaked at $19.2K in Q1 2025.
  • 253 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q1 2026.

Based on Spire Wealth Management's 13F filing for Q1 2026, filed 22 Apr 2026.